What are the sources of elevated chromogranin A (CgA) levels?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 18, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Sources of Elevated Chromogranin A (CgA)

Chromogranin A can be elevated in numerous conditions beyond neuroendocrine tumors, including medication use, organ dysfunction, and various pathological states, which must be considered when interpreting elevated levels. 1, 2

Neuroendocrine Tumors

  • CgA is elevated in 60% or more of patients with both functioning and non-functioning pancreatic neuroendocrine tumors, making it the best general neuroendocrine serum marker available 1
  • Highest levels are typically observed in patients with carcinoid tumors, with particularly high frequency of elevation in gastrinomas (100%), pheochromocytomas (89%), carcinoid tumors (80%), and nonfunctioning pancreatic endocrine tumors (69%) 3
  • Medullary thyroid carcinomas show elevated CgA in approximately 50% of cases 3
  • Elevated CgA levels strongly correlate with tumor volume, meaning small neuroendocrine tumors may go undetected with this marker alone 1, 3

Non-Neuroendocrine Tumors

  • Hepatocellular carcinoma may show elevated CgA levels in over one-third of patients, possibly indicating neuroendocrine differentiation in some cases 4
  • Prostate cancer can demonstrate elevated CgA levels, which may be independent of prostate-specific antigen (PSA) elevation 5
  • Some adenocarcinomas may show elevated CgA levels due to neuroendocrine differentiation, which can be confirmed with specialized immunohistochemical techniques 6

Medication-Induced Elevations

  • Proton pump inhibitors (PPIs) cause significant false elevations in CgA levels and should be discontinued at least 1 week before measurement 7, 1, 8
  • Antacids can also affect CgA levels and should be considered when interpreting results 7

Organ Dysfunction

  • Renal failure can cause markedly elevated CgA levels that may reach concentrations otherwise seen only in neuroendocrine neoplasia 9, 1
  • Hepatic failure can result in increased CgA levels, though typically not as dramatic as renal failure 9

Other Conditions

  • Chronic gastritis, particularly atrophic gastritis, can lead to elevated CgA levels 1, 6
  • Hypertension has been associated with spuriously elevated CgA levels 1
  • Venipuncture alone can result in modest increases (approximately 12%) in plasma CgA levels 9

Clinical Considerations

  • When evaluating elevated CgA, it's essential to rule out medication effects (especially PPIs) and organ dysfunction before attributing the elevation to neuroendocrine pathology 1, 8
  • CgA levels exceeding twice the normal limit are associated with shorter survival times in patients with metastatic NETs (HR, 2.8; 95% CI, 1.9–4.0; P<.001) 1
  • Rising CgA levels in an asymptomatic patient with stable imaging does not necessarily indicate the need for new therapy 1, 8

Complementary Markers

  • When CgA results are equivocal, consider testing for chromogranin B, which may be elevated when CgA is in the reference range 1, 8
  • Pancreastatin is specifically elevated in metastatic neuroendocrine tumors and not affected by conditions that commonly elevate CgA 1, 8
  • 5-Hydroxyindoleacetic acid (5-HIAA) is particularly useful for serotonin-producing tumors 1, 8

References

Guideline

Chromogranin A in Neuroendocrine Tumors

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Role of Chromogranin A in Pheochromocytoma Diagnosis and Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Clinical significance of elevated serum chromogranin A levels.

Scandinavian journal of gastroenterology, 2004

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Tumor Markers for Appendiceal Cancers

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.